Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Ionis Pharmaceuticals Inc (IONS)

458 + Investors. Track Smart Money conviction in IONS. See who's accumulating, reducing, or initiating positions.

Fetching live quote...
Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↓ -55
Streak
1Q ▼
Buyers last Q
46%

Smart Money Signals — IONS

Based on 462 hedge funds · latest filing: 2026 Q3 · updated quarterly

📉

Selling streak — 1 quarter in a row

last 6Q
For 1 consecutive quarter, more hedge funds reduced or closed their IONS positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.
📊

High ownership — 89% of 3.0Y peak

89% of all-time peak
462 funds currently hold this stock — 89% of the 3.0-year high of 517 funds (reached 2026 Q2). Ownership is elevated but not yet at maximum concentration. Room to grow, but watch if the trend reverses.
📶

Steady growth — +5% more funds vs a year ago

fund count last 6Q
+24 new funds entered over the past year (+5% YoY). Gradual, steady growth in institutional ownership is generally a healthy signal — not a speculative rush, but consistent conviction.
🟠

More sellers than buyers — 46% buying

248 buying291 selling
Last quarter: 291 funds reduced or exited vs 248 that bought or added. When more than half of active funds are selling, it's a caution flag — especially if the stock price hasn't moved down yet.
➡️

Steady new buyers — ~66 new funds per quarter

new funds entering per quarter
Funds opening this position for the first time: 114 → 74 → 70 → 66. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.
🔒

59% of holders stayed for 2+ years

■ 59% conviction (2yr+) ■ 26% medium ■ 15% new
273 out of 462 hedge funds have held IONS for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
💎

Buying through price weakness — shares -10%, value -43%

Value
-43%
Shares
-9%
Last quarter: funds added -10% more shares while total portfolio value only changed -43%. Institutions were buying while the price was falling — a high-conviction accumulation signal. They're deliberately loading up on the dip.
📊

Peak discovery — momentum slowing

116 → 114 → 74 → 70 → 66 new funds/Q
New funds entering each quarter: 114 → 74 → 70 → 66. IONS is well-known in the hedge fund world, but fresh entries are gradually declining. The explosive phase of institutional discovery is likely behind us.
🏛️

Veteran-anchored — 68% veterans vs 20% newcomers

■ 68% veterans ■ 13% 1-2yr ■ 20% new
Entry-cohort mix of 493 holders: 333 (68%) are 2+ year veterans, 63 entered 1–2 years ago, and 97 (20%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
🏆

Elite ownership — 67% AUM from top-100 funds

67% from top-100 AUM funds
66 of 458 holders are among the 100 largest funds by AUM, controlling 67% of total institutional value in IONS. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.
3.1
out of 10
Low Exit Risk
Exit risk score 3.1/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — IONS

In 2026 Q3, 248 hedge funds were net buyers of IONS (66 opened a new position, 182 added to an existing one), while 291 reduced or exited (170 trimmed, 121 sold completely) — a 46% buyer ratio, indicating roughly balanced activity. 67% of total institutional value in IONS is held by top-100 AUM funds, reflecting elite-tier ownership quality. Net fund flow last quarter: -55 funds (more exits than new entries). Total institutional holders: 462.

Hedge Fund Ownership: IONS

How many hedge funds hold IONS — quarterly history vs. share price
Quarterly hedge fund ownership of IONS vs. share price

Market Analysis: IONS

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: IONS

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Ionis Pharmaceuticals Inc (IONS) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much IONS has moved relative to its sector benchmark (XLV) since the 2026 Q3 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End September 30, 2026 · 50d ago
IONS
-40.1%
XLV
+7.6%

IONS outperformed XLV by -47.7% since September 30, 2026.

Since 13F Filing Date November 14, 2026 · 5d ago
IONS
-7.9%
XLV
-4.1%

Since the filing became public, IONS outperformed XLV by -3.8% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

16 top-rated funds 9 high-conviction
Consensus
5.3
/ 10
breadth
×
Elite
4.4
/ 10
conviction
Hedge Fund Positioning: IONS
458 + Investors

Track Smart Money conviction in IONS. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q3) Prior (2026 Q2) Change
Funds Holding 458 517 -11.41%
13F Shares 181M 201M -9.89%
Total Value $8.03B $14.16B -43.31%
New Positions 66 70 -4
Increased Positions 173 204 -31
Closed Positions 121 49 +72
Reduced Positions 161 159 +2
Total Calls 19 24 -20.83%
Total Puts 16 15 6.67%
PUT/CALL Ratio 0.84 0.62 Neutral

Statistics: IONS

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q3)

458 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in IONS. Verified SEC 13F-HR filings.

QUARTER:
Top 25 IONS holders by conviction (% of portfolio weight) — 2026 Q3 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Davern Capital Partners, LP 9.44% 1,087,142 $48.5M
2 Tweedy, Browne Co LLC 6.52% 1,793,400 $80.1M
3 Jones Hill Capital LP 4.55% 599,826 $26.8M
4 Great Point Partners LLC 4.48% 420,000 $18.8M
5 Exome Asset Management LLC 3.12% 107,034 $4.8M
6 Sector Gamma As 3.04% 330,037 $14.7M
7 Privium Fund Management B.V. 3.02% 349,003 $15.6M
8 Superstring Capital Management LP 2.96% 132,339 $5.9M
9 Orion Investment Co 2.61% 220,785 $9.9M
10 Tetragon Partners GP Ltd 2.57% 440,930 $19.7M
11 Deerfield Management Company, L.P. 1.84% 2,660,669 $118.8M
12 Sicart Associates LLC 1.66% 159,294 $6.8M
13 Global Alpha Capital Management Ltd. 1.27% 436,785 $19.5M
14 Ground Swell Capital, LLC 1.26% 12,254 $547K
15 PFM Health Sciences, LP 0.85% 190,905 $8.5M
16 CM Management, LLC 0.75% 25,000 $1.1M
17 AlphaCentric Advisors LLC 0.64% 16,163 $722K
18 Ishara Investments LP 0.59% 16,000 $714K
19 Axq Capital, LP 0.53% 90,552 $4.0M
20 Nicola Wealth Management LTD. 0.52% 104,000 $4.6M
21 Groupama Asset Managment 0.51% 982,789 $43.9M
22 Carmignac Gestion 0.46% 754,000 $33.7M
23 Pier Capital, LLC 0.45% 69,240 $3.1M
24 Nippon Life Global Investors Americas, Inc. 0.41% 228,630 $10.2M
25 Integral Health Asset Management, LLC 0.41% 150,000 $6.7M
Investor Ownership
History
% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Stocks with similar institutional ownership

BC 464 holdersZETA 464 holdersMSGS 463 holdersAOR 462 holdersUSRT 462 holdersHR 462 holdersICLN 462 holdersMATX 461 holdersEPAM 461 holdersBHF 461 holdersGXO 461 holdersUSIG 461 holders All stocks →

Frequently Asked Questions — Ionis Pharmaceuticals Inc (IONS)

What does the Smart Money Trend signal show for IONS?

Selling streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds reduced or closed their IONS positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for IONS?

More sellers than buyers — 46% buying: Last quarter: 291 funds reduced or exited vs 248 that bought or added. When more than half of active funds are selling, it's a caution flag — especially if the stock price hasn't moved down yet.

What is the fund quality score for IONS holders?

Elite ownership — 67% AUM from top-100 funds: 66 of 458 holders are among the 100 largest funds by AUM, controlling 67% of total institutional value in IONS. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held IONS?

59% of holders stayed for 2+ years: 273 out of 462 hedge funds have held IONS for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Ionis Pharmaceuticals Inc (IONS) following the 2026 Q3 hedge fund 13F filings?

As of today, IONS has moved -7.9% since the 2026 Q3 13F filing date (November 14, 2026), compared to -4.1% for the XLV sector ETF — an outperformance of -3.8%. Since the quarter end (September 30, 2026), IONS has gained -40.1% vs +7.6% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →